About Ronald Oudiz, MD
Investigator, The Lundquist Institute
Professor of Medicine, David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension, The Lundquist Institute
Dr. Oudiz is a specialist in cardiovascular disease, with particular focus on pulmonary hypertension and right heart failure. He has participated in more than 100 clinical trials of novel drugs and modalities to treat pulmonary vascular disease. Dr. Oudiz' area of interest within pulmonary vascular disease is heart and lung function during exercise, and using measurements of cardiopulmonary gas exchange to evaluate and manage patients with pulmonary hypertension.
About The Liu Center
The Liu Center is dedicated to providing the best and most current therapy available for patients with primary and secondary pulmonary hypertension.
The Liu Center staff specialize in the newest FDA approved therapy of bosentan (Tracleer), ambrisentan (Letairis),sildenafil (Revatio), tadalafil (Adcirca), macitentan (Opsumit), selexipag (Uptravi) subcutaneous and intravenous treprostinil (Remodulin), oral treprostinil (Orenitram), iloprost (Ventavis), inhaled treprostinil (Tyvaso), and continuous 24-hour infusion of Prostacyclin (Flolan). We also offer novel new agents for those qualified to participate in our many research protocols
About Primary Plmonary Hypertension (PPH)
- Primary pulmonary hypertension (PPH) is a rare disease that affects approximately 2-3 patients per million worldwide each year and is responsible for about 125-150 deaths per year in the United States. In most cases, PPH untreated is rapidly fatal.
- The average time to diagnosis in patients with PPH is two years. The presumed reason is due to the fact that an extensive workup is necessary to elucidate the cause of a patient's elevated pulmonary artery pressure, and the early symptoms are non-specific. Survival in patients with PPH who are untreated is approximately 30% at 3 years.
- Common symptoms of PPH are shortness of breath, weakness, and fainting episodes. Women are more likely to be symptomatic than men.
Balancing Virtual and In-Person Care
- Ronald J. Oudiz, M.D., and Traci Stewart, R.N., discuss the importance of in-person medical care to manage your pulmonary hypertension (PH). They address concerns around COVID-19 exposure and provide safety information and guidelines to help patients feel comfortable and confident when visiting their treatment centers. PHA thanks Janssen Pharmaceuticals, Inc. for its Diamond sponsorship of the PHA Connects fund, which sponsors patient education programming.
ICD-10 Codes and Nomenclature for Classification of PAH
Dr. Ronald Oudiz discusses "ICD-10 Codes and Nomenclature for Classification of PAH," from Toronto, CA.